Modakafusp alfa dose modifications
| Action on study drug or reason for dose modification . | n (%) for indicated dose of modakafusp alfa . | n (%), total (N = 146) . | |
|---|---|---|---|
| 120 mg q4w (n = 71) . | 240 mg q4w (n = 75) . | ||
| Action on study drug | 41 (57.7) | 44 (58.7) | 85 (58.2) |
| Dose reduced | 3 (4.2) | 6 (8.0) | 9 (6.2) |
| Dose rate reduced | 8 (11.3) | 8 (10.7) | 16 (11.0) |
| Dose rate increased | 1 (1.4) | 1 (1.3) | 2 (1.4) |
| Drug delay | 32 (45.1) | 38 (50.7) | 70 (47.9) |
| Drug infusion interrupted | 14 (19.7) | 8 (10.7) | 22 (15.1) |
| Reason for dose modification | |||
| AE | 36 (50.7) | 42 (56.0) | 78 (53.4) |
| Other | 13 (18.3) | 9 (12.0) | 22 (15.1) |
| Action on study drug or reason for dose modification . | n (%) for indicated dose of modakafusp alfa . | n (%), total (N = 146) . | |
|---|---|---|---|
| 120 mg q4w (n = 71) . | 240 mg q4w (n = 75) . | ||
| Action on study drug | 41 (57.7) | 44 (58.7) | 85 (58.2) |
| Dose reduced | 3 (4.2) | 6 (8.0) | 9 (6.2) |
| Dose rate reduced | 8 (11.3) | 8 (10.7) | 16 (11.0) |
| Dose rate increased | 1 (1.4) | 1 (1.3) | 2 (1.4) |
| Drug delay | 32 (45.1) | 38 (50.7) | 70 (47.9) |
| Drug infusion interrupted | 14 (19.7) | 8 (10.7) | 22 (15.1) |
| Reason for dose modification | |||
| AE | 36 (50.7) | 42 (56.0) | 78 (53.4) |
| Other | 13 (18.3) | 9 (12.0) | 22 (15.1) |